Document Detail

β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
MedLine Citation:
PMID:  23212147     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To investigate the safety and efficacy of mirabegron for patients with overactive bladder (OAB) that is unresponsive to antimuscarinic agents or is related to benign prostatic hyperplasia (BPH).
METHODS: Fifty-two newly diagnosed OAB patients (M group) and 45 patients with OAB that was unresponsive to antimuscarinics (S group) received mirabegron 50 mg once daily and were evaluated by OAB symptom score (OABSS), IPSS-QOL index, and IPSS at the time of baseline, 4 and 8 weeks. Newly diagnosed OAB patients treated with antimuscarinic agents were compared as controls.
RESULTS: Mirabegron was effective for 85.2 % in M group. Significant improvements were seen in each domain of OABSS, and there was no significant difference with antimuscarinic therapy. Mirabegron was efficacious for 61.6 % of S group, and significant decreases of OABSS and IPSS-QOL index were observed. Significant improvements were also seen in voiding symptoms in men. Post-void residual urine volumes before and after treatment were 32.1 and 34.8 ml, and 26.2 and 31.3 ml in M and S group, respectively, and there was no significant difference. The incidence of adverse events was 8.4 %, although none were serious, and the patients recovered spontaneously after mirabegron was discontinued.
CONCLUSION: The present study suggests mirabegron is as effective as antimuscarinics for OAB. It improves OAB symptoms in patients with OAB for which antimuscarinic agents are insufficient. This study revealed that mirabegron improves not only OAB symptoms related to BPH, but also voiding symptoms in men. Low and mild incidences of side effects support the safe utility of mirabegron.
Hideo Otsuki; Takeo Kosaka; Kenzo Nakamura; Junnji Mishima; Yoshitaka Kuwahara; Takuji Tsukamoto
Related Documents :
24627787 - A fixed-dose randomized controlled trial of olanzapine for psychosis in parkinson dis...
23508367 - Prevalence of psychological symptoms in contemporary chinese rural-to-urban migrant wor...
17190847 - Brand versus generic alendronate: gastrointestinal effects measured by resource utiliza...
19844097 - Safety and efficacy of iv-tpa for ischaemic stroke in clinical practice--a bayesian ana...
23783007 - Duloxetine is effective in treating depression in multiple sclerosis patients: an open-...
25062067 - Frequency and correlates of maladaptive responses to paranoid thoughts in patients with...
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article     Date:  2012-12-02
Journal Detail:
Title:  International urology and nephrology     Volume:  45     ISSN:  1573-2584     ISO Abbreviation:  Int Urol Nephrol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-30     Completed Date:  2013-08-26     Revised Date:  2014-05-26    
Medline Journal Info:
Nlm Unique ID:  0262521     Medline TA:  Int Urol Nephrol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  53-60     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetanilides / adverse effects,  therapeutic use*
Adrenergic beta-3 Receptor Agonists / adverse effects,  therapeutic use*
Muscarinic Antagonists / therapeutic use
Prostatic Hyperplasia / etiology,  ultrasonography
Quality of Life
Severity of Illness Index
Thiazoles / adverse effects,  therapeutic use*
Urinary Bladder, Overactive / complications,  drug therapy*
Reg. No./Substance:
0/Acetanilides; 0/Adrenergic beta-3 Receptor Agonists; 0/Muscarinic Antagonists; 0/Thiazoles; MVR3JL3B2V/mirabegron
Comment In:
J Urol. 2014 May;191(5):1344-6   [PMID:  24745510 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Variation of clinical and laboratory features in chronic dialysis patients treated with high-flux he...
Next Document:  Role of asymmetric dimethylarginine in the progression of carotid atherosclerosis in renal transplan...